Scottish cell therapy company TC BioPharm Limited has appointed administrators after failing to secure sufficient funding to continue operations, marking a dramatic fall for a biotech firm that once harboured ambitions to become Scotland’s first billion-dollar company listed on NASDAQ.
Michael Magnay and Rob Croxen of Alvarez & Marsal Europe LLP were appointed as joint administrators on 2 October 2025, and have launched an accelerated sale process for the company’s business and assets, including its valuable intellectual property portfolio.
TC BioPharm’s administration follows a turbulent period for its parent company, TC BioPharm Holdings (TCBH), which was delisted from NASDAQ in March 2025 after failing to maintain the exchange’s minimum $1 share price requirement. The company subsequently transitioned to over-the-counter trading, but attempts to secure new funding proved unsuccessful amid constrained capital markets and diminished investor appetite for early-stage biotechnology companies.
The holding company had originally listed on NASDAQ in February 2022 with a valuation of approximately $119 million, raising $17.5 million to fund clinical trials. However, the stock price collapsed dramatically, with shares falling over 94% in value during 2025.
“TC BioPharm is a pioneering, clinical-stage cell therapy company with an experienced and highly skilled team,” said Michael Magnay, joint administrator. “As Joint Administrators, our priority is to run a sale process at pace, and we encourage any parties interested in acquiring the business and assets, which include the intellectual property, to reach out to us as soon as possible.”
Clinical-Stage Gamma Delta T-Cell Therapy Developer
Founded in 2014 by scientist Angela Scott, TC BioPharm emerged as an early developer of allogeneic gamma-delta T cell therapies for cancer treatment. The company’s lead product, OmnImmune (TCB-002), was undergoing Phase 2/3 clinical trials for acute myeloid leukaemia (AML), making it one of the most advanced gamma delta T cell therapies globally.
The Motherwell-based firm operated from an advanced research and development facility, employing a small team of specialist scientists and support staff. The company had achieved several clinical milestones, including FDA orphan drug designation for TCB-002 in March 2022.
Angela Scott, the company’s co-founder and chief operating officer, brought extensive experience from her work with the Imperial Cancer Research Fund and PPL Therapeutics, where she was part of the team that cloned Dolly the sheep. Her vision was to develop safer, less expensive CAR-T products that could target more cancers while causing fewer side effects than existing treatments.
Market Context and Industry Challenges
TC BioPharm’s collapse reflects broader difficulties facing the UK biotechnology sector. British biotech IPOs fell to their lowest levels in a decade during 2022, with only £28 million raised across four companies, compared to £4.5 billion in 2021. The challenging funding environment has been exacerbated by reduced government R&D tax credits and diminished global investor appetite for early-stage biotech ventures.
The gamma delta T cell therapy market, while promising, remains in early development stages. More than 25 gamma delta T cell therapies are currently in clinical trials worldwide, but none have achieved commercial availability as of 2025. These therapies offer potential advantages over conventional CAR-T treatments, including the ability to operate without major histocompatibility complex (MHC) dependence and reduced risk of graft-versus-host disease.
Administration Process and Future Prospects
The administrators have confirmed that no immediate redundancies are being made while they conduct the sale process. TC BioPharm Holdings plc continues to operate separately from the administration process, though the sale of core intellectual property and R&D assets poses significant challenges for the parent company’s long-term viability.
The administration presents an opportunity for other biotechnology companies or investors to acquire TC BioPharm’s technology platform, experienced scientific team, and ongoing clinical programmes. The company’s gamma delta T cell expertise and regulatory approvals could prove valuable to organisations seeking to advance cell therapy development.